Delta-Fly Pharma, Inc. (4598.T)

Delta-Fly Pharma, Inc. (4598.T) — VMCI valuation read

Delta-Fly Pharma, Inc. sits at VMCI 25/100, with the Healthcare sector median at 50. That 25-point spread is the first thing to note on 4598.T: it tells the reader the composite is unfavorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on 4598.T are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on 4598.T: 4598.T trades at 18.0x earnings, 0% above the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 12.0% sits 2.0pp above the Healthcare median (10.0%). The Risk read: net debt to EBITDA of 2.8x is the rate-sensitivity line to watch, anchoring the bear scenario on a measurable balance-sheet metric.

4598.T fell 3.4% over the trailing 7 days, with a +7.0% read on a 30-day basis.